A STUDY OF REGULATORY MOLECULES INVOLVED IN HEPATOCARCINOGENESIS IN A TRANSGENIC MOUSE MODEL
A STUDY OF REGULATORY MOLECULES INVOLVED IN HEPATOCARCINOGENESIS IN A TRANSGENIC MOUSE MODEL
批准号:
15590631
负责人:
NAKAMOTO Yasunari
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hepatocellular carcinoma (HCC) is a common complication of chronic viral hepatitis. Recently, we have reported that Fas ligand (FasL) is critically involved in the induction of chronic immune-mediated liver cell injury that increases HCC incidence (J Exp Med 196 : 1105, 2002) ; however, the molecular mechanisms potentially responsible for carcinogenesis are not well defined. In the current study, we asked the regulatory molecules in liver diseases that displayed different procarcinogenic potentials in a hpatitis B virus (HBV) transgenic mouse model. The results are summarized as follows.1)Transfer of CD8^+-enriched splenocytes caused prolonged disease kinetics and a marked increase in the extent of hepatocyte apoptosis and regeneration. In 12 out of 14 mice the transfer resulted in multiple hepatocellular carcinomas (HCCs) comparable to the manifestations seen in the mice transferred with total splenocytes. In contrast, mice that had received CD4^+-enriched cells demonstrated lower lev … More els of liver disease and developed fewer incidences of HCC (4 of 17). The experiment also revealed that all the groups of mice complicated with HCC developed comparable mean numbers and sizes of tumors. B cell depletion had no effect on disease kinetics in this model. (Cancer Res. 64 : 3326, 2004)2)During more than twelve months of disease progression, 352 (1.7 % of all) genes were expressed differentially between the mice treated with anti-FasL Ab and with PBS (P<0.05), 190 genes of which were assigned to functional groups based on Gene Ontology categories. In the gene groups of enzymes, cell communication, cellular components, signal transduction, and nucleic acid binding, the significant changes due to anti-FasL Ab treatment were observed in 43(1.6% of the gene group), 42(2.0%), 31(1.3%), 28(1.4%), and 22(1.8%) genes, respectively. In the cell communication group, high proportion (4.3%) of cell death control genes was involved in this expression dynamics.3)We identified several genes expressed differentially at the pre-malignant lesions. Among these genes, we focused on Pim-3, which is reported as a member of a proto-oncogene Pim family, but its contribution to hepatocarcinogenesis remains elusive. The mRNA expression was selectively detected in human hepatoma cell lines, but not in normal liver tissues. Pim-3 protein was also expressed in human hepatocellular carcinoma tissues and cell lines but not in normal hepatocytes. Moreover, cell proliferation was attenuated in human hepatoma cell lines, HepsB and HuH7, by RNA interference ablation of Pim-3 gene expression. (Int.J.Cancer 114 : 209, 2005)Taken together, these data suggest the molecular mechanisms potentially responsible for hepatocarcinogenesis and the future studies for the development of molecular targets. Less
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Nakamoto Y, Suda T, et al.: "Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B."Cancer Res.. (in press). (2004)
Nakamoto Y、Suda T 等人:“慢性乙型肝炎转基因小鼠模型中淋巴细胞亚群的不同致癌潜力。”Cancer Res..(出版中)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Tsuchiyama T, Kaneko S, Nakamoto Y, et al.: "Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma."Cancer Gene Ther.. 10
Tsuchiyama T、Kaneko S、Nakamoto Y 等人:“表达单纯疱疹病毒胸苷激酶和单核细胞趋化蛋白 1 的双顺反子腺病毒载体对肝细胞癌的增强抗肿瘤作用。”癌症基因治疗.. 10
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nakamoto Y, Kaneko S, et al.: "Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A^*2402 peptide tetramers."J.Med.Virol.. 70(1). 51-61 (2003)
Nakamoto Y、Kaneko S 等人:“使用 HLA-A^*2402 肽四聚体分析日本慢性丙型肝炎患者的 CD8 阳性 T 细胞反应。”J.Med.Virol.. 70(1)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Lu P, Nakamoto Y, et al.: "Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas."Am.J.Pathol.. 162(4). 1249-1258 (2003)
Lu P、Nakamoto Y 等人:“人肝癌中内源性产生的白细胞介素 1 诱导的 CCR1 与其配体 CCL3 之间的潜在相互作用。”Am.J.Pathol.. 162(4)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1158/0008-5472.can-03-3817
发表时间:
2004-05-01
期刊:
CANCER RESEARCH
影响因子:
11.2
作者:
[Nakamoto, Y, Suda, T, Kaneko, S]
通讯作者:
Kaneko, S
共 12 条
Development of combination methods with dendritic cells and novel chemokine products for preventing hepatocellular carcinoma recurrence
-
批准号:23659396
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:NAKAMOTO Yasunari
-
依托单位:
Research of innovative development of antagomirs regulating inflammation-associated carcinogenesis in hepatic microenvironment
-
批准号:22390149
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.56万
-
财政年份:2010
-
负责人:NAKAMOTO Yasunari
-
依托单位:
Research of oncomiRs contributing to initiation process of inflammation-associated carcinogenesis in liver
-
批准号:19390198
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.4万
-
财政年份:2007
-
负责人:NAKAMOTO Yasunari
-
依托单位:
国内基金
海外基金
登录
查看更多内容
雷特综合症致病蛋白MeCP2在DNA损伤修复中的功能及分子机制研究
-
批准号:32070780
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:刘红美
-
依托单位:
组蛋白去乙酰化酶SirT7翻译后修饰及其在调控肿瘤耐药中的作用研究
-
批准号:32070770
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:孙莲慧
-
依托单位:
新的FANCM关联蛋白复合物FMAP150-FMAP160调控FANCM修复停滞复制叉的作用及机制
-
批准号:32070716
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:ZHIJIANG YAN
-
依托单位:
激活SENP1-Sirt3轴改善线粒体健康对延缓衰老的作用与机制研究
-
批准号:92049113
-
项目类别:重大研究计划
-
资助金额:60.0万元
-
批准年份:2020
-
负责人:王田实
-
依托单位:
小鼠Pold4介导的基因组稳定性在肺癌发生发展中的功能和机制研究
-
批准号:31900512
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:周忠诚
-
依托单位:
DNA损伤诱导的KIFC1磷酸化介导肿瘤耐药和复发的机制及策略研究
-
批准号:31970720
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:范广建
-
依托单位:
果蝇新基因dNKAP调控R-loop水平和基因组稳定性的分子机制及其在肿瘤发生中的功能研究
-
批准号:31970668
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:戈万忠
-
依托单位:
KLF14翻译后修饰及其在调控肿瘤细胞死亡中的作用研究
-
批准号:31970736
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:王传贵
-
依托单位:
XPF蛋白的乙酰化修饰在DNA损伤修复中的功能与作用机制研究
-
批准号:31970664
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2019
-
负责人:刘婷
-
依托单位:
有丝分裂检查点激酶对遗传稳定性的维持及其在癌症中的失调
-
批准号:31871361
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2018
-
负责人:Jungseog Kang
-
依托单位: